There is no set period of time for how long ibrutinib should be taken before it can be discontinued, and patients who are eligible to take the drug will generally take it until the disease progresses or unacceptable toxicity occurs. Ibrutinib is a tyrosine kinase inhibitor, and is indicated as a single agent for patients with set-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one prior therapy, and is taken at the recommended dosage once a day at approximately a fixed time, and is not discontinued until the disease has progressed or until unacceptable toxicity occurs. Ibrutinib may have adverse reactions such as bleeding, leukopenia, and interstitial lung disease, and is contraindicated in those who are allergic to it.Female patients should avoid pregnancy during the medication and for 1 month after the end of treatment, and breastfeeding should be discontinued in lactating females while taking the medication in order to avoid serious adverse reactions in the infant. Drugs must be applied under the guidance of a doctor, do not use on their own.